#MolecularImaging in Focus Series: The First Three Episodes
www.diagnosticimaging.com/view/molecul...
#radiology #RadRes #NuclearMedicine #ProstateCancer

Radium-223 Treatment Outcomes in Patients with Metastatic Castration-Resistant #ProstateCancer :

A Taiwan-Japan Collaborative Cohort Study

www.sciencedirect.com/science/arti... #OpenAccess #cancer

#trends today for 'prostate cancer' 'japanese prime' & 'max verstappen'

Click/Tap below:

www.newsmason.com?query=%22pro...

www.newsmason.com?query=%22jap...

www.newsmason.com?query=%22max...

#prostatecancer #japaneseprime #maxverstappen

Metformin Raises Exercise-Associated Metabolite Lac-Phe in Prostate Cancer Patients on Hormone Therapy A new study from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine found that the common diabetes drug metformin can increase levels of N-lactoyl-phenylalanine (Lac-Phe), a metabolite typically elevated after intense exercise. This effect was observed in prostate cancer patients, even when they were not physically active. Led by Dr. Marijo Bilusic and colleagues, the research published in EMBO Molecular Medicine shows that metformin mimics one key metabolic signal associated with exercise. Lac-Phe is produced when lactate combines with phenylalanine during periods of metabolic demand and has been linked to appetite regulation and weight control. In the study, patients taking metformin showed Lac-Phe levels similar to those seen after strenuous exercise, despite the metabolic disruptions caused by hormone therapy, which often leads to fatigue, weight gain, and increased cardiovascular risk. Importantly, the rise in Lac-Phe did not correlate with anti-tumor effects as measured by PSA levels, indicating it primarily supports metabolic health rather than directly fighting the cancer. The findings were consistent across different metabolic therapies. Researchers emphasize that while metformin is not a replacement for exercise, it may help counter treatment-related metabolic strain when physical activity is limited. Co-authors including Priyamvada Rai and David B. Lombard highlighted the importance of addressing whole-patient metabolic health during cancer care. This transdisciplinary work connects clinical observations with molecular biology, offering potential new strategies to improve quality of life for prostate cancer patients undergoing hormone therapy.

Metformin Raises Exercise-Associated Metabolite Lac-Phe in Prostate Cancer Patients on Hormone Therapy

🤖 IA: It's not clickbait ✅
👥 Usuarios: It's not clickbait ✅

#metformin #prostatecancer #metabolism

View full AI summary:

Real-world validation is key for AI in oncology.

This study highlights multimodal and image-only digital pathology biomarkers validated using multi-institutional data, an important step toward clinical adoption.

Learn more: buff.ly/n4nHxqy

#ProstateCancer #ArteraAI

My father was just diagnosed with prostate cancer.

My uncle on my mom’s side died from it.

It’s hereditary and it’s deadly but easily addressed if caught on time.

Latino men, get your prostate checked. ✅ 🏥

#ProstateCancer #Cancer #CancerSucks #Health #Disabilities

Fig. 2. Representative treatment plan of salvage proton (compared with photon) SBRT for locally recurrent PCa. 30 Gy to whole gland + 40 Gy SIB to DIL at base/seminal vesicle junction. (Left) proton plan, (Center) photon plan, (Right) excess bladder, penile and rectal radiation with photons compared to protons.

Up to half of #prostatecancer recurrences following #EBRT occur exclusively within the prostate - read a #PTCOG Genitourinary Subcommittee evaluation of the advantages & challenges of PT for radio-recurrent prostate cancer: www.sciencedirect.com/science/arti...

Life expectancy matters in prostate cancer decisions—but it’s not always discussed. This study highlights key barriers: concerns about patient receptiveness, communication challenges, and low confidence in LE estimates @TimDaskivich #JGIM #ProstateCancer rdcu.be/e1mpt

Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial Along with the known survival benefits, the clinically meaningful delays in pain progression and time to deterioration of overall wellbeing support consideration of darolutamide plus ADT as a standard-of-care treatment option in patients with mHSPC.

Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive #prostatecancer (ARANOTE): secondary and exploratory analyses www.thelancet.com/journals/lan... #Cancer

April 10,2026

ALL GOOD THINGS…🥹

Thx🙏🏽 to the patients & so many amazing people @thenci & beyond in my 21+yrs

Many good Friends on the Journey

Dr. Melissa Abel continues the research:#PSMA+ #BCR & #cytokines #ProstateCancer #immunotherapy

The future @ NCI is bright☀️

World Health Day, 7 April. Prevention begins with knowledge.

Prevention begins with knowledge.

This #WorldHealthDay, the CLEAR-PC project emphasizes the role of health literacy in prostate cancer prevention and care.

Join us to improve health literacy:
🔗 www.clearpc.eu/stakeholders

#CLEARPC #EU4Health #HealthLiteracy #ProstateCancer

Our newest #ProstateCancer #supportgroup is here. Gay or bisexual men diagnosed with prostate cancer have particular concerns. Addressing them with your peers is far easier! 🏳️‍🌈
2nd Sundays 5:00pm ET
www.gotomeet.me/ancanschmier

Who’s most at risk for prostate cancer, and how is treatment evolving?

This episode breaks down risk factors, screening, and how care is becoming more personalized.

Listen here: buff.ly/WikqXR0

#ProstateCancer #ArteraAI #PrecisionMedicine

One year ago today, completed 28 days of radiation treatment for early onset prostate cancer. Cured. PSA down from 8.1 to 0.69. Shout out to @cityofhope.bsky.social in #Temecula for an amazing job, team, support and follow ups. Not dead yet :) #Prostate #prostatecancer

@garethrichards.bsky.social @sheffielduni.bsky.social wants to develop new, innovative ways to monitor and treat #ProstateCancer.

In 2022, we funded Gareth to explore adrenomedullin as a biomarker and therapeutic target for prostate cancer.

📙Read more here: prostatecanceruk.org/research/res...

📣The anti-obesogenic metabolite, Lac-Phe, is elevated by #metformin treatment in #ProstateCancer patients

By M. Bilusic, D. Lombard, P. Rai & colleagues at University of Miami Miller School of Medicine

🗞️ doi.org/10.1038/s44321-026-00408-6

Original post on indieweb.social

So hopeful for these trials to create a vaccine for some of the deadliest of #cancer:

“BNT122 is the candidate more ambitious...A sample of the patient's tumor is taken, the genome is sequenced to identify up to 20 unique mutations,& a personalized mRNA vaccine is built that contains the […]

Some thoughts on the management of #BCR #ProstateCancer #EMBARK

Coming 🔜 in The Oncologist w/Dr. Melissa Abel & Dr. Fatima Karzai

“EMBARK In Biochemically Recurrent Prostate Cancer: A Journey for Some but not Most”

VR glasses soothe patients undergoing TRUS-guided prostate biopsy Prostate biopsy patients who view nature-based video content via VR glasses reported having less anxiety and more comfort.

Patients who viewed 3D nature-based video content through the glasses had less urinary retention while not showing any significant differences in other complications compared to patients undergoing the standard treatment #radiology #virtualreality #prostatecancer #ultrasound

ASCO_GU_ 2025_Social_Media_Report.pdf drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view

🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TRxgfp !

#Oncology #SocialListening #LucidQuest

Prostate Cancer Awareness Matters. 🎗️
Early detection, informed decisions, and the right treatment approach can significantly improve outcomes.

#ProstateCancer #CancerAwareness #RadiationTherapy #RTT #Oncology #Healthcare #EarlyDetection #CancerCare #GART #MedicalEducation

MR fingerprinting technique characterizes prostate lesions The technique can differentiate suspicious prostate lesions from clinically insignificant lesions.

The technique allows for simultaneous quantification of T1 and T2 images #radiology #MRI #prostatecancer

Can salvage #brachytherapy cure recurrent #prostatecancer? The new RESPRO study shows it can, with a 93.6% rate of 10-year overall survival!
💡 A major step forward for real-world evidence in #radonc.
👉 Read the full interview with co-authors: bit.ly/4mdNXxK

Two medical monitors display MRI scans. The left screen shows a grid of four different cross-sectional images of internal body parts. The right screen focuses on one larger, detailed MRI scan.

📚 Update your knowledge and practice

New, free online course on Early Detection in Prostate Cancer in collaboration @bmj.com.

Topics include:

🔹Risk
🔹PSA testing
🔹Patient referral & more

⭐ Earn 1 CPD point

Start learning ➡️ buff.ly/1erx4gI

#prostatecancer #CPD

Cognitive frailty in elderly prostate cancer patients affects outcomes.

📢Join the 12th Edition of the International Conference on Aging & Gerontology

🗓May 11–12, 2026 | Tokyo, Japan

Website: agingcongress.com

#ProstateCancer #CognitiveFrailty #Gerontology #Oncology

Metformin boosts an exercise-linked metabolite and may help control weight in prostate cancer patients Metformin raised the exercise-linked metabolite Lac-Phe in prostate cancer patients across disease stages and treatment settings, while Lac-Phe itself did not predict anticancer response. Patients in ...

Metformin may mimic some exercise benefits in prostate cancer patients, boosting Lac-Phe - a metabolite linked to better weight control during treatment. 🏃‍♂️💊
www.news-medical.net/news/2026040... #ProstateCancer #Metformin #Cancer @embo.org

Dr. Adam Kinnaird wins the EAU Imaging Vision Award for his OPTIMUM trial, recognized as the year’s most innovative urological imaging study.
He also wins a $570K grant for a trial comparing micro ultrasound vs mpMRI for prostate cancer screening.
#Urology #ProstateCancer

Trial Tuesday! Dr. Deepak Kilari from Medical College of Wisconsin is now enrolling Alliance for Clinical Trials in Oncology A032302 (ASPIRE) to see if adding chemo to hormone therapy improves survival in men with metastatic #prostatecancer. Learn more at http://bit.ly/AllianceA032302

Scientific Paper published in The Journal of Clinical Investigation, titled: Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers. Written by Paschalis et al.

Could AR mutation status serve as a predictive biomarker for AR‑targeted therapies in #ProstateCancer?

A team led by Prof de Bono at @icr.ac.uk, supported by our Movember London Centre of Excellence, share findings in @jci.org.

Grab a ☕ & read: doi.org/10.1172/JCI1...

Hubby is officially half way through his chemo treatments.

If you have a prostate, get it checked regularly!

#CancerSucks #ProstateCancer #Cancer